Introduction
B-cell chronic lymphoproliferative disorders (B-CLPD) usually show a monoclonal expansion of a (single) mature-appearing aberrant B-cell clone. [1] [2] [3] [4] However, patients diagnosed with composite lymphomas and other B-cell chronic lymphocytic leukemias -e.g. chronic lymphocytic leukemia (CLL) -have been reported in the literature for decades, particularly among immunocompromised subjects. [5] [6] [7] Although early reports considered this phenomenon as a rare event, it might have been underestimated due to the need for sophisticated multidisciplinary approaches encompassing combined histopathology, cytomorphology, immunophenotypic and cytogenetic techniques and/or molecular analyses of purified cell populations. 8 In fact, B-cell neoplasms consisting of two phenotypically distinct populations of clonally unrelated B-lymphocytes coexisting in the same patient (detected either simultaneously or at different time points during follow-up) have been reported in the literature, 9,10 with an estimated overall frequency among B-CLPD patients of around 5%. 11 Recently, it has also been shown that up to 20% of population-based non-CLL and CLL-like low count monoclonal B-cell lymphocytosis (MBL lo ) cases may also carry two different unrelated B-cell clones. [12] [13] [14] In addition, data from a small series suggest that the frequency of multiclonality could be particularly high among CLL-like MBL cases from CLL relatives, (4/6 cases analysed). 12 Altogether, these results support the existence of multiclonality in a significant proportion of both MBL cases and B-CLPD patients.
Multiclonal MBL and B-CLPD cases may consist of expansions of ≥ 2 B-cell clones potentially associated with chronic antigen-driven immune responses. [15] [16] [17] In fact, this is particularly frequent at the earlier MBL lo stages, which would further support the potential reactive nature of MBL among individuals with normal lymphocyte counts, prior to the stepwise acquisition of genetic alterations and progression to clinical MBL (MBL hi ) and CLL. 13, 14, 18, 19 If this hypothesis holds true, specific antigenic determinants could potentially be more frequently shared between the coexisting B-cell clones of multiclonal cases than between the expanded Bcells in different monoclonal MBL and B-CLPD patients, due to a greater probability of interaction with common immunological determinants. This might even be true when the 5 coexisting clones display clearly distinct immunophenotypic and cytogenetic, as well as clinical features.
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In order to test this hypothesis, in the present study we compared the B-cell receptor (BCR) repertoire and molecular profile, as well as the phenotypic, cytogenetic and hematological features of CLL-like and non-CLL-like clones (n=228) from multiclonal (n=41 cases) vs monoclonal cases (n=143, including both CLL and CLL-like MBL -n=128-, as well as B-CLPD patients other than CLL and non-CLL-like MBL subjects -n=15-). Peripheral blood samples were obtained from each subject after written informed consent was given, and the study was approved by the local ethics committees of the University Cytogenetic and molecular studies. Cytogenetic analyses were performed by multicolor interphase fluorescence in situ hybridization on slides containing FACS-purified and fixed 7 aberrant B-cells, as previously described in detail. 18, 30 In parallel, analysis of the patterns of rearrangement of the immunoglobulin heavy chain variable region genes (IGHV) and immunoglobulin K (IGKV) and λ (IGLV) light chain genes was performed for each FACS-purified B-cell clone 18, [31] [32] (see the Online Supplementary Methods section for detailed descriptions).
Methods

Patients and samples.
To investigate the level of phylogenetic relationship among IGHV aminoacid sequences, a sequence distance tree was built using the neighbor-joining method implemented in the freely available Molecular Evolutionary Genetic Analysis (MEGA) software. 33 Two different co-existing
BCRs were considered as being phylogenetically related when their IGHV aminoacid sequences, going from framework region 1 to HCDR3 (both regions included) showed an identity ≥ 60%. This "identity" threshold was based on previously published concepts about the phylogeny of human IGHV genes based on their aminoacid sequences 33 , and on the minimum identity percentage observed in colocalized sub-branches (presumably with the highest evolutionary relationship 33 ) of the sequence distance tree built in this study (see the Online
Supplementary Methods section for more detailed descriptions). HCDR3-alignments were carried out for each multiclonal case whose co-existing B-cell clones showed HCDR3 regions with identical or one aminoacid differing lengths using the bioinformatic tools available at the web services of the European Bioinformatics Institute (EMBL-EBI Cambridge, UK). Through the EMBL-EBI tools, the identical aminoacids or those with analogous side-chain polarity per paired intra-case HCDR3-alignment were highlighted (see the Online Supplementary Methods section for more detailed descriptions).
Statistical methods. For all statistical analyses the SPSS software program (SPSS 20.0, IBM SPSS Statistics, IBM, Armonk, NY, USA) was used. Table 2 ). The complete immunophenotypic and cytogenetic features of the individual clones of multiclonal cases are summarized in Supplementary Table 3 .
Results
Distribution and immunophenotypic features of B-cell clones.
In 26/41 multiclonal cases, all coexisting B-cell clones showed a CLL-like phenotype, while in 11 of the remaining 15 cases, at least one CLL-like B-cell population coexisting with another non-CLL aberrant B-cell population was identified. In the remaining 4 cases, two distinct non-CLL-like B-cell clones were found (Supplementary Table 3 Table 2 ). The precise diagnoses of the B-cell clones from B-CLPD patients other than CLL are specified in the footnote of Supplementary Table 2 ). Of note, these differences were mostly due to the lower frequency of B-cell clones with del(13q14) (4% vs 19%, P=0.01) found among CLL clones from multiclonal vs monoclonal cases (Table 2) .
No statistically significant differences were observed in the cytogenetic patterns of non-CLL B-cell clones from multiclonal vs monoclonal cases, which is probably due to the relatively low number of non-CLL clones included in the study; the precise cytogenetic alterations found in non-CLL / non-CLL-like MBL cases are shown in Supplementary Tables 3 and 4 Figure 1A ). Interestingly, 11 of these IGHV genes were found at similar frequencies within the clones of multiclonal vs monoclonal cases, while the V3-33 gene was typically associated with multiclonal cases (6% vs 1%, P=0.03). Regarding IGHD genes, no significant differences were observed between B-cell clones from multiclonal and monoclonal cases, the D3-3, D5-12, D3-10, D6-19, D2-15, and D2-2 genes being the most frequently used and shared by both groups of B-cell clones ( Figure 1B ). Among IGHJ genes, significant differences were only observed for the JH6 gene, which was more frequently used in monoclonal cases (40% vs 26%, P= 0.03) ( Figure 1C ).
Except for slightly longer LCDR3 sequences of the IGKV and IGLV genes found among B-cell clones from multiclonal versus monoclonal cases, specially among CLL-like MBL hi clones (Table 3) , no other significant differences were found in the molecular characteristics of the immunoglobulin light chain genes, neither among CLL-like nor non-CLL like B-cell clones from multiclonal vs monoclonal cases (Table 3 and Supplementary Table 5 Table   6 ) showed a tendency towards a lower homology than that of multiclonal cases: median of 37%
(range: 11% to 71%) vs 50% (range: 26% to 64%), respectively; (P=0.1). Since stereotyped sequences are widely represented in CLL, 34 we further analyzed the frequency of stereotyped HCDR3 sequences in multiclonal cases (Table 4B) vs. monoclonal cases (Table 4C) .
Interestingly, the number of multiclonal cases showing the same or highly similar stereotyped HCDR3 sequences was significantly higher than that of monoclonal cases: 8/41 (19%) vs 11/143 (8%), respectively, (P=0.001). Furthermore, the aminoacid composition of HCDR3
sequences from monoclonal cases with stereotyped HCDR3 sequences showed clearly less identical and/or conserved positions than those found among multiclonal cases (underlined aminoacids in Tables 4B and 4C) . Results expressed as number of B-cell clones from all clones in the corresponding group (percentage) or as *median (range). CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MBL, monoclonal B-cell lymphocytosis; BCR, B-cell receptor; HCDR3, heavy chain complementarity-determining region 3; LCDR3, light chain complementarity-determining region 3; aa, amino acid. NA, not analyzed; a statistically significant differences found between groups of clones from multiclonal vs monoclonal cases (P ≤ 0.03).
Table 4. Multiclonal cases with coexisting B-cell clones sharing HCDR3 features (A). Multiclonal (B) and monoclonal (C) cases with B-cell clones showing stereotyped HCDR3 aminoacid sequences.
A. Multiclonal cases with coexisting B-cell clones showing identical or one aa differing length of HCDR3 regions, and analogous composition of aa in some parallel positions. major branch, having IGHV sequences with an aminoacid identity which is > 60% (-68%, 73%, 73.4%, 61%, 79%, 70%, 63%, 77%, 69.9%, 70%, 72% and 68.4%-, respectively). ; in every case, the phenotypic study was extended with additional 5-and 6-color stainings, as reported elsewhere.
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Data acquisition for ≥5x10 6 leucocytes/tube was performed in FACSCanto II flow cytometers (BD) using the FACSDiva software (V6.1; BD). Instrument setup, calibration and daily monitoring were performed according to the EuroFlow protocols. 26 For data analysis, the Infinicyt TM software (Cytognos SL, Salamanca, Spain), was used. The minimum number of clustered events required to define a B-cell population was of 50 cells.
Purification of B-cell populations.
In all cases studied, each sIg light chain restricted and phenotypically aberrant B-cell population identified was purified in a FACSAria II flow cytometer (BD). In those samples (n=41) containing ≥2 aberrant B-cell populations, discrimination among them was based on their distinct patterns of expression for ≥1 of the B-cell markers analyzed, as described elsewhere. 29 The clonal nature of each FACS-purified B-cell population (purity: 98%±0.8%) was assessed by both cytogenetic and molecular techniques, as described below. Sequences containing >2% deviation from the germline sequence were considered as being somatically mutated.
Each deduced "IMGT/V-QUEST aminoacid (aa) sequence" corresponding to individual IGHV gene sequences from purified B-cell clones from both monoclonal and multiclonal cases was aligned using the bioinformatic tools available at the web services of the European Bioinformatics Institute (EMBL-EBI Cambridge, UK). More than 12,400 alignments of IGHV aminoacid sequences, with a coverage ranging from framework region (FR) 1 to the HCDR3 region (both regions included) were obtained for all B-cell clones (a total of 8,891 alignments within the monoclonal and 3,560 alignments within the multiclonal groups of cases).Then, the percentage of alignment of IGHV aminoacid sequences obtained after two-bytwo comparisons between the distinct B-cell clones, was calculated for every pair of B-cell clones. Finally, each single paired-alignment obtained -8,891 and 3,560 in monoclonal vs. multiclonal cases, respectivelywas included in a final database, to calculate the median and range of the total IGHV aminoacid alignment percentages and to calculate the statistical significance of their differences observed between the two groups (p-values).
To investigate the level of phylogenetic relationship among IGHV aminoacid sequences corresponding to distinct clones from multiclonal cases, as well as monoclonal cases, a sequence distance tree was built using the neighbor-joining method implemented in the freely available Molecular Evolutionary Genetic Analysis (MEGA) software (version 5.2, http://www.megasoftware.net). 33 Examination of the different branches of the sequence distance tree allowed the distinction of multiclonal cases whose clones had IGHV aminoacid sequences phylogenetically closer than others. Thus, sequences in the same major branch were guaranteed to exhibit ≥50% aminoacid identity (from FR1 to HCDR3, both regions included).
33
As might be expected, sequences in sub-branches emerging from the same major branch exhibit even more aminoacid identity, ranging from 60% to 99%. In our analysis, those co-existing B-cell clones with IGHV aminoacid sequences that belonged to the same major branch with >60% aminoacid identity or belonged to close located sub-branches were assumed to be "phylogenetically" related sequences.
Those HCDR3 regions with an identical length or a length differing in one aminoacid were (case-paired)
analyzed using the EMBL-EBI tools to determine those positions which had an identical or conserved composition in terms of "hydropathy", "volume" and " Age values expressed as *media ± one standard deviation (range) when n>2. MBL, monoclonal B-cell lymphocytosis; CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; B-CLPD, B-cell chronic lymphoproliferative disorders other than CLL or MBL. probes (13q14, 13q14.3, 17p13.1 and 11q22.3) . The presence of genetic abnormalities in one population was always evaluated in the other coexisting population. ¶Cases whose clones had IGHV aa sequences phylogenetically closer than those found in the rest of multiclonal cases. 
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